Actively Recruiting

Phase 2
Age: 35Years - 70Years
FEMALE
NCT06568705

Hypofractionated Online Adaptive Radiotherapy of Breast Cancer

Led by Peking Union Medical College Hospital · Updated on 2026-03-20

40

Participants Needed

1

Research Sites

117 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to explore the application of online adaptive radiotherapy in patients who receive moderate hypofractionated or ultrafractionated radiotherapy after breast cancer surgery. The main questions it aims to answer are: * Can online adaptive radiotherapy improve the accuracy of dose delivery? * In patients undergoing online adaptive radiotherapy, how are the treatment-related toxicities and tumor control outcomes? Participants will Receive moderate hypofractionated radiotherapy using online adaptive radiotherapy, a dose of 43.5Gy in 15 fractions or receive ultrafractionated radiotherapy using online adaptive radiotherapy, a dose of 26Gy in 5 fractions.

CONDITIONS

Official Title

Hypofractionated Online Adaptive Radiotherapy of Breast Cancer

Who Can Participate

Age: 35Years - 70Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female, aged 6535 years and under 70 years
  • ECOG performance status score of 0 to 2
  • Have undergone breast-conserving surgery or modified radical mastectomy, with or without sentinel lymph node biopsy or axillary lymph node dissection
  • Pathologically confirmed primary breast cancer diagnosis
  • For patients without neoadjuvant therapy: pathological stage pT0-2N0-1; for those with neoadjuvant therapy: staged ypT0-2N0-1
  • Indicated for and planned to undergo postoperative adjuvant radiotherapy
  • Able to cooperate with and tolerate the treatment
Not Eligible

You will not qualify if you...

  • Pathologically confirmed metastasis in supraclavicular or infraclavicular lymph nodes, or distant metastasis
  • History of radiotherapy to the neck or chest
  • Contraindications or intolerance to radiation therapy, including pregnancy or lactation; severe heart, lung, kidney, liver, or other vital organ impairment; severe infection or blood abnormalities; brachial plexus nerve injury on the affected side; active connective tissue diseases
  • History of other malignant tumors

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peking Union Medical College Hospital

Beijing, China

Actively Recruiting

Loading map...

Research Team

X

Xiaorong Hou, MD

CONTACT

X

Xiaorong Hou

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here